Step-down affordable treatment for chronic hepatitis B infection in Africa: feasibility of treatment strategy

Queen Mary University of London (UK)0 个研究点目标入组 80 人开始时间: 2014年3月31日最近更新: 2021年5月24日

适应症

试验速览

2017 baseline liver pathology in https://pubmed.ncbi.nlm.nih.gov/29378031/ (added 10/05/2021)

•1. HBV viral load >105 copies/ml
•2. Alanine aminotransferase (ALT) >1.3 times upper limit of normal (which sets the criterion at 45 i.u./l)
•3. Evidence of inflammation on liver biopsy
•4. May be either e antigen negative (n=40) or positive (n=40)

•1. Histological or radiological evidence of cirrhosis
•2. HIV infection
•3. History of alcohol abuse or histological evidence of alcoholic liver disease
•4. History of any long-term drug ingestion
•5. Histological evidence of metabolic liver disease (haemochromatosis, Wilson?s disease, a1-antitrypsin deficiency) or autoimmune liver disease [antibodies to M2 antigen, Perinuclear antineutrophil cytoplasmic antibodies (p-ANCA), nuclear antigens, microsomes or smooth muscle]
•6. Histological or radiological evidence of schistosomiasis
•7. Histological evidence of hepatitis D virus (HDV) infection
•8. Virological evidence of active hepatitis C virus (HCV) or hepatitis E virus (HEV) infection

发起方

Queen Mary University of London (UK)